RU2008132327A - Применение lactobacillus paracasei для предупреждения или лечения нервно-мышечных нарушений кишечника - Google Patents

Применение lactobacillus paracasei для предупреждения или лечения нервно-мышечных нарушений кишечника Download PDF

Info

Publication number
RU2008132327A
RU2008132327A RU2008132327/13A RU2008132327A RU2008132327A RU 2008132327 A RU2008132327 A RU 2008132327A RU 2008132327/13 A RU2008132327/13 A RU 2008132327/13A RU 2008132327 A RU2008132327 A RU 2008132327A RU 2008132327 A RU2008132327 A RU 2008132327A
Authority
RU
Russia
Prior art keywords
lactobacillus paracasei
treatment
prevention
preparation
food composition
Prior art date
Application number
RU2008132327/13A
Other languages
English (en)
Other versions
RU2490325C2 (ru
Inventor
Ирен КОРТЕЗИ-ТЕЛАЗ (CH)
Ирен КОРТЕЗИ-ТЕЛАЗ
Де БЕРЦИК Элен ВЕРДЮ (CA)
де БЕРЦИК Элен ВЕРДЮ
Премисл БЕРЦИК (CA)
Премисл БЕРЦИК
Стивен Майкл КОЛЛИНС (CA)
Стивен Майкл КОЛЛИНС
Original Assignee
Нестек С.А. (Ch)
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29797269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2008132327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нестек С.А. (Ch), Нестек С.А. filed Critical Нестек С.А. (Ch)
Publication of RU2008132327A publication Critical patent/RU2008132327A/ru
Application granted granted Critical
Publication of RU2490325C2 publication Critical patent/RU2490325C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения нарушений двигательной функции, мышечных сокращений или сократимости кишечника, возникающих после инфекции, и боли или дискомфорта, возникающих при указанных нарушениях. ! 2. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для лечения синдрома раздраженного кишечника. ! 3. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения нарушений двигательной функции, мышечных сокращений или сократимости кишечника после инфекции, возникающих при занятиях физкультурой и спортом. ! 4. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения младенческих колик. ! 5. Применение по любому из пп.1-4, в котором Lactobacillus paracasei выбран из группы, состоящей из Lactobacillus paracasei CNCM 1-2116 и Lactobacillus paracasei CNCM 1-1292 и их смесей. ! 6. Применение по любому из пп.1-4, в котором Lactobacillus paracasei включает мертвые бактерии Lactobacillus paracasei, ферментационный субстрат и/или полученный из Lactobacillus paracasei материал.

Claims (6)

1. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения нарушений двигательной функции, мышечных сокращений или сократимости кишечника, возникающих после инфекции, и боли или дискомфорта, возникающих при указанных нарушениях.
2. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для лечения синдрома раздраженного кишечника.
3. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения нарушений двигательной функции, мышечных сокращений или сократимости кишечника после инфекции, возникающих при занятиях физкультурой и спортом.
4. Применение пробиотика Lactobacillus paracasei для приготовления пищевой композиции или лекарственного средства для предупреждения или лечения младенческих колик.
5. Применение по любому из пп.1-4, в котором Lactobacillus paracasei выбран из группы, состоящей из Lactobacillus paracasei CNCM 1-2116 и Lactobacillus paracasei CNCM 1-1292 и их смесей.
6. Применение по любому из пп.1-4, в котором Lactobacillus paracasei включает мертвые бактерии Lactobacillus paracasei, ферментационный субстрат и/или полученный из Lactobacillus paracasei материал.
RU2008132327/10A 2002-07-23 2003-07-23 Применение lactobacillus paracasei cncm i-2116 для лечения синдрома раздраженного кишечника RU2490325C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078064.9 2002-07-23
EP02078064A EP1384483A1 (en) 2002-07-23 2002-07-23 Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005104950/13A Division RU2346036C2 (ru) 2002-07-23 2003-07-23 Пробиотики для нервно-мышечной функции кишечника

Publications (2)

Publication Number Publication Date
RU2008132327A true RU2008132327A (ru) 2010-02-10
RU2490325C2 RU2490325C2 (ru) 2013-08-20

Family

ID=29797269

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005104950/13A RU2346036C2 (ru) 2002-07-23 2003-07-23 Пробиотики для нервно-мышечной функции кишечника
RU2008132327/10A RU2490325C2 (ru) 2002-07-23 2003-07-23 Применение lactobacillus paracasei cncm i-2116 для лечения синдрома раздраженного кишечника

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2005104950/13A RU2346036C2 (ru) 2002-07-23 2003-07-23 Пробиотики для нервно-мышечной функции кишечника

Country Status (18)

Country Link
US (1) US8021656B2 (ru)
EP (2) EP1384483A1 (ru)
JP (1) JP2005538087A (ru)
KR (1) KR20050025978A (ru)
CN (1) CN100480370C (ru)
AT (1) ATE534396T1 (ru)
AU (1) AU2003250149B2 (ru)
BR (1) BR0313185A (ru)
CA (1) CA2493255A1 (ru)
ES (1) ES2376664T3 (ru)
IL (1) IL166442A0 (ru)
MX (1) MXPA05000880A (ru)
NO (1) NO20050896L (ru)
NZ (1) NZ538335A (ru)
PT (1) PT1531841E (ru)
RU (2) RU2346036C2 (ru)
WO (1) WO2004009103A1 (ru)
ZA (1) ZA200501559B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518191A (ja) * 2003-01-09 2006-08-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 細菌ワクチンベクターの免疫原性を強化するための組成物、方法、及びキット
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
TR201820329T4 (tr) * 2005-02-28 2019-01-21 Nutricia Nv Probiyotik İçeren Besin Bileşimi
ZA200711054B (en) * 2005-07-20 2009-09-30 Unilever Plc Edible product containing beneficial moulds and/or yeasts
WO2007038466A2 (en) * 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
WO2007093619A1 (en) 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
MY149913A (en) * 2006-03-07 2013-10-31 Nestec Sa Synbiotic mixture
EP2021011A2 (en) * 2006-05-26 2009-02-11 Nestec S.A. Methods of use and nutritional compositions of touchi extract
KR101521123B1 (ko) * 2006-05-28 2015-05-19 시플라 메드프로 리서치 앤드 디벨롭먼트 (피티와이) 엘티디 프로바이오틱 스트레인 및 그로부터 유도된 항균 펩티드
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
ES2399775T3 (es) * 2007-10-11 2013-04-03 Dupont Nutrition Biosciences Aps Composiciones farmacéuticas que comprenden L. acidophilus y bifidobacterium lactis para el uso en el tratamiento de un trastorno intestinal funcional
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium
CA2724554A1 (en) * 2008-05-15 2009-11-19 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
EP2216034A1 (en) * 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus helveticus CNCM I-4095 and weight control
WO2010103132A1 (es) * 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
CN102802648A (zh) * 2009-05-11 2012-11-28 雀巢产品技术援助有限公司 约氏乳杆菌La1 NCC533(CNCM I-1225)和免疫病症
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
CA2787544C (en) * 2010-01-28 2019-07-09 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
ES2610359T3 (es) * 2010-08-10 2017-04-27 Chr. Hansen A/S Composición nematicida que comprende Bacillus subtilis y Bacillus licheniformis
EP2455094A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
JP5681533B2 (ja) * 2011-03-14 2015-03-11 ビオフェルミン製薬株式会社 消化管痛の予防又は軽減剤
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US20130045185A1 (en) * 2011-08-18 2013-02-21 Dupont Nutrition Biosciences Aps Strains and methods useful for mycotoxins
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
US20130251829A1 (en) 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
CA2885537C (en) * 2012-09-20 2021-11-23 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
MX2015005165A (es) * 2012-10-25 2015-10-29 Gervais Danone Sa Cepas de streptococcus thermophilus para tratar infeccion por helicobacter pylori.
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2014196913A1 (en) 2013-06-03 2014-12-11 Björck Inger Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella
CA3176938A1 (en) * 2013-08-09 2015-02-12 Ab-Biotics, S.A. Probiotic for infantile excessive crying
CN103497988B (zh) * 2013-09-23 2014-10-29 广州康代生物科技有限公司 一种安全高效乳酸菌产品的发酵生产方法
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
RU2608871C1 (ru) * 2015-11-06 2017-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" Штамм бактерий Lactobacillus paracasei 1, используемый для приготовления пробиотического препарата
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
CN105767507B (zh) * 2016-03-30 2020-12-01 遂平广源饲料科技有限公司 一种饲料用微生态制剂、无抗饲料及其制备方法
KR101765559B1 (ko) * 2016-09-27 2017-08-07 이대희 노루궁뎅이버섯을 포함하는 프로바이오틱스 조성물
WO2020132411A1 (en) * 2018-12-21 2020-06-25 Kimberly-Clark Worldwide, Inc. Compositions and methods for preventing or treating incontinence, overactive bladder, or menstrual cramping

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
EP1034787A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
EP1034788A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
BR0008920A (pt) * 1999-03-11 2001-12-18 Nestle Sa Cepas de lactobacillus capazes de prevenirdiarréia causada por bactéria patogênica erotaviroses
TR200200301T2 (tr) * 1999-08-05 2004-12-21 Societe Des Produits Nestle S.A. Patojenik bakterilerin sebep olduğu ishali ölemeye elverişli bifidobakteriler
AU784898B2 (en) * 2000-01-18 2006-07-20 Societe Des Produits Nestle S.A. Pet food composition for treating helicobacter species in pets
AU783439C (en) * 2000-03-24 2006-12-14 Societe Des Produits Nestle S.A. Use of lactic acid bacterium for the prevention of peritonitis
JP2003535903A (ja) 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
EP1408760B1 (en) * 2001-02-19 2009-04-01 Société des Produits Nestlé S.A. Consumable product containing probiotics
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Also Published As

Publication number Publication date
WO2004009103A1 (en) 2004-01-29
EP1531841A1 (en) 2005-05-25
JP2005538087A (ja) 2005-12-15
BR0313185A (pt) 2005-06-21
AU2003250149B2 (en) 2009-01-22
NZ538335A (en) 2007-04-27
CN100480370C (zh) 2009-04-22
RU2005104950A (ru) 2005-12-10
ATE534396T1 (de) 2011-12-15
EP1531841B1 (en) 2011-11-23
AU2003250149A1 (en) 2004-02-09
EP1384483A1 (en) 2004-01-28
MXPA05000880A (es) 2006-01-24
US20070128178A1 (en) 2007-06-07
RU2490325C2 (ru) 2013-08-20
US8021656B2 (en) 2011-09-20
NO20050896L (no) 2005-04-18
IL166442A0 (en) 2006-01-15
KR20050025978A (ko) 2005-03-14
ZA200501559B (en) 2006-05-31
PT1531841E (pt) 2012-02-01
CN1678329A (zh) 2005-10-05
CA2493255A1 (en) 2004-01-29
ES2376664T3 (es) 2012-03-15
RU2346036C2 (ru) 2009-02-10

Similar Documents

Publication Publication Date Title
RU2008132327A (ru) Применение lactobacillus paracasei для предупреждения или лечения нервно-мышечных нарушений кишечника
Ojetti et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial
TWI574633B (zh) 包含益生菌及益生質成分及礦物鹽及乳鐵蛋白之組合物
Oyetayo et al. Potential of probiotics as biotherapeutic agents targeting the innate immune system
BR112012018813B1 (pt) composição compreendendo cepas bacterianas com atividade anti-inflamatória, imunomoduladora, antiibs ou antidistensão abdominal, uso das mesmas, bem como produtos farmacêutico, veterinário e comestível compreendendo a referida composição
JP2018184481A (ja) 機能性消化管障害予防及び／又は改善剤
RU2008107935A (ru) Применение специфических молочнокислых бактерий для получения иммуномодулирующих композиций
KR20210079312A (ko) 운동 후 염증을 개선시키거나 체지방을 감소시키기 위한 락토바실러스 플란타룸 twk10 조성물의 방법
Nagaraj et al. Probiotics and oral health
CN107095308A (zh) 一种益生菌制剂及其应用
JP2008054556A (ja) 免疫賦活作用及び／又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌
TW201216866A (en) Intestine immunomodulator
TW201818828A (zh) 抑制腸道內乳桿菌屬乳酸菌減少用之組成物
Karvonen et al. Safety and possible anti-diarrhoeal effect of the probiotic Lactobacillus reuteri after oral administration to neonates
CN100374148C (zh) 一种用于防治动物泻痢的口服液
Isolauri The use of probiotics in paediatrics
JP6218280B2 (ja) 唾液分泌促進剤
ES2966935T3 (es) Composiciones de lactobacillus plantarum y sus usos
US20200188453A1 (en) Method of a lactobacillus plantarum twk10 composition for improving inflammation after exercise
Irin et al. Health Benefits of Probiotics from Fermented Foods in Bangladesh.
JP2012136450A (ja) インフルエンザウイルス感染予防用組成物
CN111297912A (zh) 胚芽乳酸杆菌twk10制备抗运动后发炎或降体脂组合物的用途
CN117064921A (zh) 益生菌和唾液酸在缓解皮肤氧化损伤和/或衰老中的应用及产品
Chawla et al. Safety issues in probiotic use
TW202021598A (zh) 胚芽乳酸桿菌ｔｗｋ１０用於製備抗運動後發炎醫藥組合物之用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180724